Journal Title：Hematological Oncology

Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders

-Diagnostic investigations, including imaging and laboratory assays

-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases

-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies

-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.

Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

《血液腫瘤學(xué)》雜志刊登的文章涉及造血和淋巴系統(tǒng)腫瘤疾病的實(shí)驗(yàn)和臨床方面以及相關(guān)事宜。特別歡迎將基礎(chǔ)科學(xué)應(yīng)用于臨床問(wèn)題的轉(zhuǎn)化研究。鼓勵(lì)投稿涉及以下領(lǐng)域的稿件：

-血液腫瘤的臨床實(shí)踐和管理，包括：急性和慢性白血病、惡性淋巴瘤、骨髓增生性疾病

-診斷研究，包括影像學(xué)和實(shí)驗(yàn)室檢測(cè)

-血液疾病的血液腫瘤的流行病學(xué)、病理學(xué)和病理生物學(xué)

-治療問(wèn)題，包括 1、2 或 3 期試驗(yàn)以及同種異體和自體干細(xì)胞移植研究

-正常或患病造血和淋巴細(xì)胞的細(xì)胞生物學(xué)、分子生物學(xué)、分子遺傳學(xué)和細(xì)胞遺傳學(xué)方面，包括干細(xì)胞和細(xì)胞因子以及其他調(diào)節(jié)系統(tǒng)。

歡迎簡(jiǎn)明扼要、主題鮮明的綜述材料，尤其是如果它能讓更廣泛的社區(qū)能夠接觸到新的概念和想法?？梢耘c主編討論評(píng)論材料的提案。只有具有更廣泛的科學(xué)或臨床相關(guān)性的病例材料和病例報(bào)告集合才會(huì)被考慮。

Hematological Oncology創(chuàng)刊于1983年，由John Wiley and Sons Ltd出版商出版，收稿方向涵蓋血液學(xué) - 醫(yī)學(xué)全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過(guò)審相對(duì)較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機(jī)率較高。平均審稿速度 12周，或約稿 ，影響因子指數(shù)3.3，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。